GENE ONLINE|News &
Opinion
Blog

2018-12-17| Trials & Approvals

Novartis’s Ligelizumab Progresses to Phase III Trial

by Rajaneesh K. Gopinath
Share To

By Rajaneesh K. Gopinath, Ph.D.

After it’s strong showing in a Phase IIb trial, the monoclonal antibody now moves to the next stage of its development as an effective therapy for chronic spontaneous urticaria (CSU).

Chronic Urticaria is an allergic skin disease that is characterized by the formation of wheals and angioedema. Chronic spontaneous urticaria (CSU) is one of the subtypes of the disease which could occur unpredictably without a trigger. Omalizumab (Xolair), is a prescribed treatment for the condition. It is a humanized monoclonal antibody that binds to Immunoglobulin E (IgE) and reduces allergic symptoms. The drug is used for the treatment of various allergic reactions including Asthma. It is considered a breakthrough drug and was recently recommended by a global guideline as an add-on therapy for CSU patients who are unresponsive to antihistamines. Xolair is marketed all over the world and in the US, it is co-promoted by Novartis Pharmaceuticals and Genentech Inc.

In recent times though, Novartis is developing yet another humanized anti-IgE monoclonal antibody called ligelizumab, for the treatment of allergic and autoimmune diseases. After promising results in a Phase IIb clinical trial comprising 382 patients, it is now advancing to Phase III trials. In the placebo- and active-controlled Phase IIb trial, ligelizumab outperformed omalizumab and met its primary endpoint by demonstrating a clear dose-response relationship. It bound IgE with greater affinity than omalizumab, and this translated into greater therapeutic efficacy. Ligelizumab achieved a rapid onset of action and improved and sustained efficacy. The results were announced at the 27th EADV Congress 2018 in Paris.

On December 4th, Novartis announced the initiation of multi-center, randomized, double-blind, active- and placebo-controlled Phase III trials – PEARL1 and PEARL 2. More than 2,000 patients will initially be randomized to ligelizumab dose A and B, omalizumab 300mg with the treatment given every 4 weeks for one year. Patients initially randomized to placebo will be switched to ligelizumab dose B starting week 24 until week 52. The primary outcome will measure absolute change from baseline in Urticaria Activity Score (UAS7) at Week 12.

Eric Hughes, Global Development Unit Head, Immunology, Hepatology and Dermatology expressed his excitement. “Novartis is committed to leveraging our strong heritage and expertise in immuno-dermatology to reimagine and discover potential new treatments which can benefit patients,” he said in a statement. “By initiating ligelizumab to Phase III studies we continue to honor that commitment”.

 

References
  1. https://www.novartis.com/news/media-releases/novartis-advances-ligelizumab-qge031-urticaria-phase-iii-basis-strong-phase-ii-head-head-data
  2. https://www.mdedge.com/edermatologynews/article/183878/urticaria/ligelizumab-outperformed-omalizumab-refractory-chronic
  3. https://www.novartis.com/news/media-releases/novartis-xolairr-recommended-new-global-chronic-urticaria-guideline

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Asthma Medications: From Quick Relief to Long-Term Control
2024-03-11
Breakthrough Study Shows Anti-IgE Antibody Safeguards Children with Multiple Food Allergies
2024-02-27
M&A
GSK Completed the Acquisition of Aiolos Bio, Enhancing the Respiratory Portfolio of Asthma
2024-02-16
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top